CA
NZ
UK
AU
IND
US
AstraZeneca (NYSE:AZN) shares are declining sharply in Wednesday's session, underperforming the broader healthcare sector, which has been comparatively resilient amid a mixed macro backdrop of oil price swings andEquitymarketVolatilitytied to AI trade rotation and looming U.S.-China trade talks. The drop comes despite routine positive …
BridgeBio Pharma (NASDAQ:BBIO) shares are extending a multi-week slide in Wednesday's session, falling further despite the company announcing new peer-reviewed real-world data showing its lead drug acoramidis, marketed as Attruby, reduced a composite of clinical worsening events by 34% versus rival tafamidis in patients …
Cullinan Therapeutics (NASDAQ:CGEM) shares are sliding sharply in Wednesday's session, giving back a significant portion of recent gains driven by updated Phase 3 REZILIENT3 data on zipalertinib, partnered with Taiho Pharmaceutical, in EGFR exon20ins non-small cell lung cancer. The underlying data itself showed a …
Hims & Hers Health (NYSE:HIMS) shares are declining sharply in Wednesday's session, extending a multi-week slide as legal and regulatory overhang deepens. A securities fraud class action was filed on September 21, with a lead plaintiff deadline of November 2, compounding the FTC's July …
Ascendis Pharma (NASDAQ:ASND) shares are sliding in Wednesday's session as investors digest the company's decision to terminate its collaboration agreement with Novo Nordisk (NYSE:NVO), reclaiming full rights to its TransCon technology-based metabolic and cardiovascular pipeline, including once-monthly TransCon Semaglutide. While the move gives Ascendis …
Apnimed (NASDAQ:APMD) shares are sliding sharply in Wednesday's session, extending a multi-day decline of over 25% from last week's levels above $29. Heavy insider and institutional selling pressure appears to be weighing on the stock following its recent addition to the S&P Total Market …
Ardent Health (NYSE:ARDT) shares declined in Wednesday's session as a research firm initiated coverage with a cautious Market Perform rating and an $11 price target, signaling limited near-term upside from the current trading price. The initiation contrasts with more bullish stances from other analysts, …
Artelo Biosciences (NASDAQ:ARTL) shares are soaring after the company filed a provisional patent application covering its drug candidate ART27.13 for the treatment of obesity, both as a standalone therapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic …
Psyence Biomedical Ltd. (NASDAQ:PBM), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, has announced a cashInvestmentof up to 5 million dollars in Psyence Labs Ltd., alongside a value-matched share exchange between the two companies. The transactions, announced on September 23, 2026, are intended to support …
Johnson & Johnson (NYSE:JNJ) has announced new model-based analysis from its Phase 3 MajesTEC-3 study, evaluating TECVAYLI plus DARZALEX FASPRO in patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. Using a relative survival mixture cure …
Please wait processing your request...